Your browser doesn't support javascript.
loading
Fatal Human Rabies Infection With Suspected Host-Mediated Failure of Post-Exposure Prophylaxis Following a Recognized Zoonotic Exposure-Minnesota, 2021.
Holzbauer, Stacy M; Schrodt, Caroline A; Prabhu, Rajesh M; Asch-Kendrick, Rebecca J; Ireland, Malia; Klumb, Carrie; Firestone, Melanie J; Liu, Gongping; Harry, Katie; Ritter, Jana M; Levine, Min Z; Orciari, Lillian A; Wilkins, Kimberly; Yager, Pamela; Gigante, Crystal M; Ellison, James A; Zhao, Hui; Niezgoda, Michael; Li, Yu; Levis, Robin; Scott, Dorothy; Satheshkumar, Panayampalli S; Petersen, Brett W; Rao, Agam K; Bell, W Robert; Bjerk, Sonja M; Forrest, Sara; Gao, Wangcai; Dasheiff, Richard; Russell, Kari; Pappas, Melissa; Kiefer, Jessica; Bickler, Wesley; Wiseman, Anthony; Jurantee, Joel; Reichard, R Ross; Smith, Kirk E; Lynfield, Ruth; Scheftel, Joni; Wallace, Ryan M; Bonwitt, Jesse.
Afiliación
  • Holzbauer SM; Minnesota Department of Health, St. Paul, Minnesota, USA.
  • Schrodt CA; Career Epidemiology Field Officer Program, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Prabhu RM; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Asch-Kendrick RJ; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Ireland M; Essentia Health, Duluth, Minnesota, USA.
  • Klumb C; Midwest Medical Examiner's Office, Ramsey, Minnesota, USA.
  • Firestone MJ; Minnesota Department of Health, St. Paul, Minnesota, USA.
  • Liu G; Minnesota Department of Health, St. Paul, Minnesota, USA.
  • Harry K; Minnesota Department of Health, St. Paul, Minnesota, USA.
  • Ritter JM; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Levine MZ; Minnesota Department of Health, St. Paul, Minnesota, USA.
  • Orciari LA; Minnesota Department of Health, St. Paul, Minnesota, USA.
  • Wilkins K; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Yager P; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Gigante CM; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Ellison JA; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Zhao H; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Niezgoda M; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Li Y; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Levis R; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Scott D; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Satheshkumar PS; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Petersen BW; US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Rao AK; US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Bell WR; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Bjerk SM; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Forrest S; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Gao W; University of Minnesota, Minneapolis, Minnesota, USA.
  • Dasheiff R; Essentia Health, Duluth, Minnesota, USA.
  • Russell K; Essentia Health, Duluth, Minnesota, USA.
  • Pappas M; Allina Health, Minneapolis, Minnesota, USA.
  • Kiefer J; Essentia Health, Duluth, Minnesota, USA.
  • Bickler W; Essentia Health, Duluth, Minnesota, USA.
  • Wiseman A; Essentia Health, Duluth, Minnesota, USA.
  • Jurantee J; Essentia Health, Duluth, Minnesota, USA.
  • Reichard RR; Essentia Health, Duluth, Minnesota, USA.
  • Smith KE; Essentia Health, Duluth, Minnesota, USA.
  • Lynfield R; Essentia Health, Duluth, Minnesota, USA.
  • Scheftel J; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Wallace RM; Minnesota Department of Health, St. Paul, Minnesota, USA.
  • Bonwitt J; Minnesota Department of Health, St. Paul, Minnesota, USA.
Clin Infect Dis ; 77(8): 1201-1208, 2023 10 13.
Article en En | MEDLINE | ID: mdl-36988328
BACKGROUND: No human rabies post-exposure prophylaxis (PEP) failure has been documented in the United States using modern cell culture-based vaccines. In January 2021, an 84-year-old male died from rabies 6 months after being bitten by a rabid bat despite receiving timely rabies PEP. We investigated the cause of breakthrough infection. METHODS: We reviewed medical records, laboratory results, and autopsy findings and performed whole-genome sequencing (WGS) to compare patient and bat virus sequences. Storage, administration, and integrity of PEP biologics administered to the patient were assessed; samples from leftover rabies immunoglobulin were evaluated for potency. We conducted risk assessments for persons potentially exposed to the bat and for close patient contacts. RESULTS: Rabies virus antibodies present in serum and cerebrospinal fluid were nonneutralizing. Antemortem blood testing revealed that the patient had unrecognized monoclonal gammopathy of unknown significance. Autopsy findings showed rabies meningoencephalitis and metastatic prostatic adenocarcinoma. Rabies virus sequences from the patient and the offending bat were identical by WGS. No deviations were identified in potency, quality control, administration, or storage of administered PEP. Of 332 persons assessed for potential rabies exposure to the case patient, 3 (0.9%) warranted PEP. CONCLUSIONS: This is the first reported failure of rabies PEP in the Western Hemisphere using a cell culture-based vaccine. Host-mediated primary vaccine failure attributed to previously unrecognized impaired immunity is the most likely explanation for this breakthrough infection. Clinicians should consider measuring rabies neutralizing antibody titers after completion of PEP if there is any suspicion for immunocompromise.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Rabia / Vacunas Antirrábicas Tipo de estudio: Prognostic_studies Límite: Aged80 / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Rabia / Vacunas Antirrábicas Tipo de estudio: Prognostic_studies Límite: Aged80 / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos